Ethylene Glycol

Ethylene Glycol

SCHEMBL1170971

O=C(O)CC(S)c1ccccc1.O=C(O)CC(S)c1ccccc1.OCCO

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GABBR2 O75899 1/20 0.48
GABBR1 Q9UBS5 1/20 0.48
CYP2C19 P33261 2/20 0.44
CPA1 P15085 2/20 0.40
CYP2D6 P10635 1/20 0.40
SRC P12931 1/20 0.40
MAPT P10636 1/20 0.40
CPB1 P15086 1/20 0.40
CPA3 P15088 1/20 0.40
CPB2 Q96IY4 1/20 0.40
LMNA P02545 2/20 0.39
MAPK1 P28482 1/20 0.39
FFAR1 O14842 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1171114 0.94 GABBR2 (0.53) GABBR2GABBR1CYP2C19CPA1CYP2D6
Hydrogen Sulfide SCHEMBL28282419 0.92 GABBR2 (0.52) GABBR2GABBR1CYP2C19CPA1CYP2D6
Di(Hydroxyethyl)Ether SCHEMBL1171208 0.88 GABBR2 (0.42) GABBR2GABBR1CYP2C19CPA1CYP2D6
SCHEMBL1171222 0.87 GABBR2 (0.44) GABBR2GABBR1CYP2C19CPA1CYP2D6
Glycerin SCHEMBL3210246 0.87 GABBR2 (0.44) GABBR2GABBR1CYP2C19CPA1MAPT
SCHEMBL1303811 0.87 GABBR2 (0.44) GABBR2GABBR1CYP2C19CPA1CYP2D6
Glycerin SCHEMBL3192940 0.87 GABBR2 (0.44) GABBR2GABBR1CYP2C19CPA1MAPT
SCHEMBL1171446 0.87 GABBR2 (0.44) GABBR2GABBR1CYP2C19CPA1CYP2D6
Propylene Glycol SCHEMBL1171246 0.85 GABBR2 (0.43) GABBR2GABBR1CYP2C19MAPTFFAR1
SCHEMBL999962 0.85 GABBR2 (0.42) GABBR2GABBR1CYP2C19CYP2D6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492293-B2 Multi-component systems for preparing foamed products ARKEMA FRANCE (FR) 2025-12-09 US disclosed
US-20250154361-A1 RECESS FILLING MATERIAL KIT, CURED PRODUCT THEREOF, AND RECESS FILLING METHOD RESONAC CORPORATION (JP) 2025-05-15 US disclosed
EP-4328206-A1 RECESS FILLING MATERIAL KIT, CURED PRODUCT OF SAME, AND RECESS FILLING METHOD Resonac Corporation (JP) 2024-02-28 EP disclosed
EP-3891210-B1 MULTI-COMPONENT SYSTEMS FOR PREPARING FOAMED PRODUCTS ARKEMA FRANCE (FR) 2023-08-23 EP disclosed
US-20230099722-A1 COMPOSITION FOR FORMING THERMALLY CONDUCTIVE MATERIAL, THERMALLY CONDUCTIVE MATERIAL, THERMALLY CONDUCTIVE SHEET, AND DEVICE WITH THERMALLY CONDUCTIVE LAYER FUJIFILM CORPORATION (JP) 2023-03-30 US disclosed
EP-4024445-A1 COMPOSITION FOR FORMING HEAT-CONDUCTING MATERIAL, HEAT-CONDUCTING MATERIAL, HEAT-CONDUCTING SHEET, AND DEVICE WITH HEAT-CONDUCTING LAYER FUJIFILM Corporation (JP) 2022-07-06 EP disclosed
US-20220033606-A1 MULTI-COMPONENT SYSTEMS FOR PREPARING FOAMED PRODUCTS ARKEMA FRANCE (FR) 2022-02-03 US disclosed
EP-3891210-A1 MULTI-COMPONENT SYSTEMS FOR PREPARING FOAMED PRODUCTS ARKEMA FRANCE (FR) 2021-10-13 EP disclosed
EP-3533809-B1 RADICAL-POLYMERIZABLE RESIN COMPOSITION SHOWA DENKO KK (JP) 2021-09-29 EP disclosed
US-11130891-B2 Photocurable sealing material BOSTIK SA (FR) 2021-09-28 US disclosed
EP-2295481-A1 CURABLE COMPOSITION CONTAINING A REACTIVE (METH)ACRYLATE POLYMER AND A CURED PRODUCT THEREOF Showa Denko K.K. (JP) 2011-03-16 EP disclosed
US-7888399-B2 Curable composition containing thiol compound SHOWA DENKO K.K. (JP) 2011-02-15 US disclosed
US-20100210812-A1 CURABLE COMPOSITION AND CURED PRODUCT THEREOF SHOWA DENKO K.K. (JP) 2010-08-19 US disclosed
US-20100087611-A1 URETHANE COMPOUND, CURABLE COMPOSITION CONTAINING THE SAME, AND CURED PRODUCT THEREOF SHOWA DENKO K.K. (JP) 2010-04-08 US disclosed
EP-2172509-A1 CURABLE COMPOSITION AND CURED PRODUCT THEREOF Showa Denko K.K. (JP) 2010-04-07 EP disclosed
US-20100029876-A1 POLYMERIZATION ACCELERATOR, CURABLE COMPOSITION, CURED PRODUCT, AND PROCESS FOR PRODUCING THIOL COMPOUND SHOWA DENKO K.K. (JP) 2010-02-04 US disclosed
EP-2143739-A1 URETHANE COMPOUND, CURABLE COMPOSITION CONTAINING THE SAME, AND CURED PRODUCT OF THE COMPOSITION Showa Denko K.K. (JP) 2010-01-13 EP disclosed
EP-2030989-A1 POLYMERIZATION ACCELERATOR, CURABLE COMPOSITION, CURED PRODUCT AND METHOD FOR PRODUCING THIOL COMPOUND Showa Denko K.K. (JP) 2009-03-04 EP disclosed
US-20090023831-A1 Curable Composition Containing Thiol Compound SHOWA DENKO K.K. (JP) 2009-01-22 US disclosed
EP-1983017-A1 CURABLE COMPOSITION CONTAINING THIOL COMPOUND Showa Denko K.K. (JP) 2008-10-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087611-A1 URETHANE COMPOUND, CURABLE COMPOSITION CONTAINING THE SAME, AND CURED PRODUCT THEREOF ITCH, GLI1, UNC119 GABBR2 734/4885GABBR1 497/4885CYP2C19 1723/4885
US-20100029876-A1 POLYMERIZATION ACCELERATOR, CURABLE COMPOSITION, CURED PRODUCT, AND PROCESS FOR PRODUCING THIOL COMPOUND TMT1A, CCNT1, MGMT GABBR2 4091/4885GABBR1 4296/4885CYP2C19 3376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.